Timing of Toll-Like Receptor 9 Agonist Administration in Pneumococcal Vaccination Impacts Both Humoral and Cellular Immune Responses as Well as Nasopharyngeal Colonization in Mice

Ítems similars

• Correction for Jensen et al., Timing of Toll-Like Receptor 9 Agonist Administration in Pneumococcal Vaccination Impacts Both Humoral and Cellular Immune Responses as Well as Nasopharyngeal Colonization in Mice
  per: Jensen, Katrine M., et al.
  Publicat: (2014)
• TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
  per: Offersen, Rasmus, et al.
  Publicat: (2012)
• The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
  per: Martinsen, Janne Tegder, et al.
  Publicat: (2020)
• Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
  per: Winckelmann, Anni A., et al.
  Publicat: (2013)
• A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4(+) T Cells
  per: Offersen, Rasmus, et al.
  Publicat: (2016)